Manitimus 是一種 dehydroorotate dehydrogenase 的抑制劑,同時為有效的免疫抑制藥。<BR><a href="https://www.medchemexpress.cn/SCH-563705.html">SCH 563705</a>產(chǎn)品描述:SCH 563705 is a potent dual CXCR2(IC50= 1.3 nM)/CXCR1(IC50= 7.3 nM) antagonist.IC50 value: 7.3 nM (CXCR1); 1.3 nM (CXCR2) [1]Target: CXCR1; CXCR2in vitro: SCH 563705 has emerged as the most potent CXCR2–CXCR1 dual antagonist to date. It has been evaluated further in a wide range of in vitro and in vivo studies. In the chemotaxis assays, it demonstrated potent inhibition against both Gro-α and IL-8 induced human neutrophil migration (chemotaxis IC50 = 0.5 nM, against 30 nM of Gro-α; chemotaxis IC50 = 37 nM, against 3 nM of IL-8) [1]. SCH563705 selectively reduced the peripheral blood neutrophil frequency, and caused an elevation in the CXCR2 ligand CXCL1 [2].in vivo: SCH 563705 achieved an ED50 of 0.9 mg/kg in the rat LPS (lipopolysaccharide) challenged model and an ED50 of 1 mg/kg in the mouse cigarette smoke induced neutrophilic inflammatory model [1].<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領域的一流供應商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/SCH-563705.html">www.medchemexpress.cn/SCH-563705.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt="">Purity:98%<BR>MWt:308.2552<BR>Formula:C15H11F3N2O2<BR>SMILES:C#CCC/C(O)=C(C#N)/C(NC1=CC=C(C(F)(F)F)C=C1)=O<BR>Pathway:Others; <BR>Mechanisms:Others; <BR>Research Area:Inflammation/Immunology<BR>電話: 021-58955995<BR>網(wǎng)址: www.MedChemExpress.cn <BR>地址: 上海市浦東新區(qū)蔡倫路720號2號樓3層 |
Manitimus前沿研究進展
發(fā)布日期:2017-11-13 瀏覽次數(shù):0
核心提示:Manitimus 是一種 dehydroorotate dehydrogenase 的抑制劑,同時為有效的免疫抑制藥。BRa href=https://www.medchemexpress.cn/S
- 下一篇:暫無
- 上一篇:Aligeron前沿研究進展
行業(yè)動態(tài)
更多...
- Manitimus前沿研究進展 11-13
- Aligeron前沿研究進展 11-13
- Bamirastine前沿研究進展 11-13
- RPR104632前沿研究進展 11-13
- PD-159020前沿研究進展 11-13
- NVX-207前沿研究進展 11-13
- Ethyl dirazepate前沿研究 11-13
- RPH-2823前沿研究進展 11-13
- Tulopafant前沿研究進展 11-13
- Fibracillin前沿研究進展 11-13